La vendita allo scoperto per ETC 6 Meridian Mega Cap Equity ETF dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di ETC 6 Meridian Mega Cap Equity ETF. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

ETC 6 Meridian Mega Cap Equity ETF (ARCA:SIXA), Report sulle vendite allo scoperto

Consumer Defensive

Technology

Financial Services

Communication Services

Consumer Cyclical

Healthcare

Industrials

Energy

Utilities

Real Estate

Other

Basic Materials

The Fund is an actively managed exchange-traded fund (ETF) that invests, under normal circumstances, at least 80 percent of its net assets (plus the amount of any borrowings for investment purposes) in mega capitalization equity securities. Madison Avenue Financial Solutions, LLC, the Funds sub-adviser (the Sub-Adviser), considers mega capitalization companies to be the largest 10 percent of stocks included in the Russell 3000 Index by market capitalization. The equity securities in which the Fund invests are mainly common stocks.

Kraft Heinz Co.

Johnson & Johnson

At&t Inc

Duke Energy Corp Sr Unsecured

Abbvie Inc.

American Express Co.

Altria Group Inc.

Caterpillar, Inc.

Colgate-Palmolive Co

Exxon Mobil Corp.

Philip Morris International Inc

At&t Inc Cdi Common Stock Usd1.0

Pepsico Inc.

Verizon Communications Inc Vz

Nvidia Corp.

Qualcomm Inc.

Chevron Corp

Southern Co.

Comcast Corp A

ETC 6 Meridian Mega Cap Equity ETF

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), a biopharmaceutical company, is engaged in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide.
It will report its Q1 2025 earnings on April 25, before the market opens. Wall Street analysts expect the company to post EPS of $2.51, up from $2.31 in the prior-year period. According to data from Benzinga Pro, quarterly revenue is expected to be $12.91 billion, up from $12.31 billion a year earlier.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>
The 52-week range of AbbVie stock price was $153.58 to $218.66.
AbbVie's dividend yield is 3.86%. It paid $6.56 per share in dividends during the last 12 months.
<h2 class="wp-block-heading">The Latest On AbbVie</h2>
On Jan. 31, the company announced its Q4 2024 earnings, posting adjusted EPS of $2.16, beating the street view of $2.11, as reported by <a href="https://www.benzinga.com/news/earnings/25/01/43392796/abbvie-jumps-after-q4-earnings-beat-skyrizi-and-rinvoq-boom-offsets-humira-decline">Benzinga</a>. Quarterly sales came in at $15.102 billion, outpacing the analyst consensus estimate of $14.827 billion.&nbsp;
AbbVie sees full-year 2025 adjusted EPS in the range of $12.12 to $12.32, compared to the street view of $12.18. The company reaffirmed its expectations for a high single-digit compound annual revenue growth rate through 2029.
Check out this <a href="https://www.benzinga.com/insights/analyst-ratings/25/03/44128338/13-analysts-have-this-to-say-about-abbvie">article by Benzinga</a> for 13 analysts' insights on AbbVie.
Trending: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
<h2 class="wp-block-heading">How Can You Earn $100 Per Month As An AbbVie Investor?</h2>
If you want to make $100 per month — $1,200 annually — from AbbVie dividends, your investment value needs to be approximately $31,088, which is around 183 shares at $170.16 each.&nbsp;
Understanding the dividend yield calculations: When making an estimate, you need two key variables — the desired annual income ($1,200) and the dividend yield (3.86% in this case). So, $1,200 / 0.0386 = $31,088 to generate an income of $100 per month.
You can calculate the dividend yield by dividing the annual dividend payments by the current price of the stock.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
The dividend yield can change over time. This is the outcome of fluctuating stock prices and dividend payments on a rolling basis.
For instance, assume a stock that pays $2 as an annual dividend is priced at $50. Its dividend yield would be $2/$50 = 4%. If the stock price rises to $60, the dividend yield drops to 3.33% ($2/$60). A drop in stock price to $40 will have an inverse effect and increase the dividend yield to 5% ($2/$40).
In summary, income-focused investors may find AbbVie stock an attractive option for making a steady income of $100 per month by owning 183 shares of stock.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

ABBV

How Much Would It Take To Earn $100 A Month From AbbVie Stock

A 25% tariff on imported cars is revving up the pressure on European luxury automakers, and high-end buyers in the U.S. could face five-figure price hikes, according to Tim Urquhart, principal automotive analyst at S&amp;P Global Mobility.
President Donald Trump said on April 10 that his administration would enforce a 25% tariff on imported vehicles as part of his broader &#8220;reciprocal trade&#8221; policy, though he has since suggested he may delay the move.
While some tariffs were delayed for 90 days, this particular levy stayed in place — and it&#8217;s hitting the ultra-luxury market hard.
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
</ul>
<h2 class="wp-block-heading">Ferrari Raises Prices as Other Brands Scramble</h2>
Ferrari <a href="https://www.ferrari.com/en-EN/corporate/articles/ferrari-commercial-policy-update">announced</a> last month that it would increase the prices of nearly all of its models sold in the U.S. by up to 10%. The hike applies even to vehicles ordered months prior, including the newly released Purosangue SUV and the 12 Cilindri grand tourer built in Maranello, Italy.
Urquhart told <a href="https://www.businessinsider.com/trumps-tariffs-threaten-us-love-affair-with-european-luxury-cars-2025-4">Business Insider</a>, "It&#8217;s very bad news. There&#8217;s no getting around that. Ferrari, Bentley, and Rolls-Royce are in a tough spot — they can't absorb a 25% tariff, so that will have to be passed on to customers."
Urquhart added that ultra-luxury brands have more pricing flexibility than mass-market automakers due to their premium sticker prices.
Rolls-Royce, a subsidiary of BMW, is still assessing the situation. <a href="https://www.theguardian.com/business/2025/mar/19/bentley-could-pass-costs-of-us-tariffs-to-buyers-due-to-drop-in-chinese-demand">Bentley</a>, owned by Volkswagen AG, will continue U.S. imports but hasn&#8217;t decided on pricing adjustments.&nbsp;
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
<h2 class="wp-block-heading">Audi, Jaguar, And Mercedes Adjust U.S. Strategies</h2>
Other European automakers are adjusting quickly. <a href="https://media.jaguarlandrover.com/news/2025/04/jlrs-statement-tariffs">Jaguar Land Rover</a> — owned by India's Tata Motors — temporarily halted U.S. shipments to evaluate the impact.&nbsp;
Audi, a Volkswagen subsidiary, was holding deliveries at U.S. ports as it weighed the next steps, according to <a href="https://www.autonews.com/volkswagen/audi/an-trump-tariffs-audi-holds-inventory-0403/">Automotive News</a>.
Mercedes-Benz is also reevaluating its lower-end lineup. As reported by<a href="https://www.bloomberg.com/news/articles/2025-04-01/mercedes-weighs-pulling-us-entry-level-cars-over-trump-tariffs"> Bloomberg</a>, Mercedes may pull some of its entry-level models from the U.S. market due to profitability concerns.
While several automakers posted strong sales gains in March, <a href="https://newsroom.porsche.com/en_US/2025/company/Q1-PCNA-Sales-39125.html">Porsche</a> reported its best-ever first quarter in the U.S., with Q1 2025 sales jumping 40.6%. The company credited strong demand for the 911 and Macan models for the record growth.&nbsp;
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
<h2 class="wp-block-heading">Tariffs Create Long-Term Headaches</h2>
The broader economic fallout could be steep. A report by<a href="https://www.andersoneconomicgroup.com/tariffs-economic-impact-on-auto-industry/"> Anderson Economic Group</a> estimated that U.S. consumers could pay over $30 billion in added costs from the tariffs in the first year alone. The report also mentioned that the average imported vehicle price could climb by $2,500 to $5,000, with ultra-luxury models rising even more.
Strategy and insight director at Cox Automotive, Philip Nothard, told<a href="https://www.businessinsider.com/trumps-tariffs-threaten-us-love-affair-with-european-luxury-cars-2025-4"> Business Insider</a> that shifting production to the U.S. to bypass tariffs would be slow and costly. "You can't just suddenly set up production plants, supply chain, and labor overnight," he said.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>
Image: Shutterstock

Ferrari, Rolls-Royce, And Bentley Prices Are About To Soar As 25% Tariff Sends Shockwaves Through U.S. Luxury Car Market

XFOR

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

STSSW

STSS

NAAS

STKH

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has outperformed the market over the past 20 years by 6.35% on an annualized basis producing an average annual return of 14.42%. Currently, Eli Lilly has a market capitalization of $797.04 billion. 
Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 20 years ago, it would be worth $15,015.11 today based on a price of $887.40 for LLY at the time of writing.
<h3>Eli Lilly's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745624717_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) has outperformed the market over the past 10 years by 7.94% on an annualized basis producing an average annual return of 18.14%. Currently, Live Nation Entertainment has a market capitalization of $30.51 billion. 
Buying $100 In LYV: If an investor had bought $100 of LYV stock 10 years ago, it would be worth $517.99 today based on a price of $132.00 for LYV at the time of writing.
<h3>Live Nation Entertainment's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745623811_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

Morningstar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORN#NASDAQ">MORN</a>) has outperformed the market over the past 20 years by 24.47% on an annualized basis producing an average annual return of 32.54%. Currently, Morningstar has a market capitalization of $12.00 billion. 
Buying $100 In MORN: If an investor had bought $100 of MORN stock 20 years ago, it would be worth $27,993.02 today based on a price of $280.63 for MORN at the time of writing.
<h3>Morningstar's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745622912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MORN

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

Grant Cardone does everything he can to minimize his income taxes. The real estate investor and bestselling author moved to Florida to avoid state income taxes, and he also uses various assets to minimize his federal income taxes.
Cardone recently laid out the playbook for reducing your taxable income on paper to keep more of what you earn. However, he started right out of the gate by telling people what they shouldn't do with their money.
"If you can't write it off, don't buy it," Cardone stated in an <a href="https://x.com/GrantCardone/status/1913579678729744714">X post</a>.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
</ul>
Anyone can use these strategies to trim their tax burden. While there are more tax-saving tactics you can use if you speak with a professional, Cardone's post offers a head start.
<h2 class="wp-block-heading">Invest In Real Assets And Claim Depreciation&nbsp;</h2>
Cardone's first tip for lowering your taxes was to invest in real assets and claim depreciation. It makes sense that this tip would be on the top of Cardone's list. He has a $5 billion real estate portfolio and regularly looks for new deals.
Real estate investors can use depreciation to artificially reduce their taxable income. However, it gets even better for investors who regularly buy properties and use Section 179 of the tax code. This part of the tax code allows an investor to write off an entire property's value in one year. For instance, if an investor earns $1 million and buys a $1.5 million property, they can show a $500,000 net loss when they report to the IRS.
Trending: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
You have to fulfill certain conditions to be eligible for Section 179 of the tax code. However, if you're eligible, you can save a lot of money while investing in real assets. This tax strategy also works with any vehicle that is more than 6,000 pounds.
<h2 class="wp-block-heading">Buy, Borrow, Die</h2>
Cardone is a fan of the "Buy, Borrow, Die" model, which involves borrowing against assets instead of selling them. Assets can gain value over time, especially inflation hedges like real estate. If you borrow against these assets instead of selling them, you don't have to pay any capital gains taxes. Furthermore, you still get to benefit from any cash flow and appreciation.
As your net worth grows, you get to borrow cash at lower interest rates. Billionaires get lower interest rates than most people because they are the banks' largest customers. As you grow wealth, it becomes cheaper to borrow money. You can gradually pay back debt and still get to keep your assets when it's all said and done.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
<h2 class="wp-block-heading">Set Up A Home Office</h2>
Business owners and side hustlers can set up home offices and deduct it for tax purposes. It's extra money that the IRS is willing to let you keep as long as you have the right documentation.
Finally, if you're going the business route, you might as well put your kids on payroll. Cardone recommends this strategy because your kids will receive a lower tax rate than you would at your highest dollar. Your children can also take advantage of the standard tax deduction to further reduce how much they pay. Meanwhile, it will show up in your finances as a business expense, which will reduce your taxable income.
Most parents want to give their children inheritances anyway. Setting them up as business employees allows you to give them the money without the government taking some of it away. You also end up with a lower tax bill.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>
Image: Shutterstock

Grant Cardone Reveals How Anyone Can Lower Their Tax Bill: 'If You Can't Write It Off, Don't Buy It'

Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) has outperformed the market over the past 10 years by 18.46% on an annualized basis producing an average annual return of 28.66%. Currently, Corcept Therapeutics has a market capitalization of $7.52 billion. 
Buying $1000 In CORT: If an investor had bought $1000 of CORT stock 10 years ago, it would be worth $11,852.89 today based on a price of $71.25 for CORT at the time of writing.
<h3>Corcept Therapeutics's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745622011_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CORT

Here's How Much $1000 Invested In Corcept Therapeutics 10 Years Ago Would Be Worth Today

Modine Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) has outperformed the market over the past 15 years by 1.48% on an annualized basis producing an average annual return of 12.15%. Currently, Modine Manufacturing has a market capitalization of $4.27 billion. 
Buying $1000 In MOD: If an investor had bought $1000 of MOD stock 15 years ago, it would be worth $5,790.86 today based on a price of $81.13 for MOD at the time of writing.
<h3>Modine Manufacturing's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745621111_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Shaquille O'Neal's life isn't divided by status—it's defined by impact. One minute he's fielding calls from billionaires, the next he's helping a <a href="https://www.benzinga.com/personal-finance/25/01/42953411/nba-star-shaq-learned-true-meaning-of-pressure-after-his-dad-took-him-to-a-homeless-family-he-paid-36000-to-get-them-off-the-streets">homeless family get an apartment</a>.&nbsp;
In 2017, he announced plans to run for sheriff in 2020 to <a href="https://youtu.be/GlhvMjeSg-c?si=hH1qoWxL2ECl8ZUU">WXIA-TV Atlanta</a>, stating, "This is not about politics. This is about bringing people closer together." Though he never officially filed, the sentiment reflected his lifelong commitment to community and connection.
"I'm a guy that speaks all languages," Shaq explained. "I can put on a suit and have a conversation with Bill Gates. I can go in the hood and talk to the homies, and talk to the children."
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
This philosophy has guided his ventures beyond basketball. A chance encounter at a hotel led to an early investment in Google. While dining at the Four Seasons, <a href="https://www.benzinga.com/personal-finance/24/10/41432168/nba-icon-shaquille-oneal-says-an-accidental-babysitting-gig-led-to-his-early-investment-in-googl">Shaq played with some children</a> whose father, impressed by his demeanor, offered him an investment opportunity in a then-little-known company called Google. Shaq invested and later remarked on "The Ellen DeGeneres Show," "I got a really big return."&nbsp;
His investment strategy was influenced by <a href="https://www.benzinga.com/personal-finance/25/03/44068159/nba-legend-shaq-says-his-net-worth-quadrupled-once-he-took-note-from-jeff-bezos-and-started-investing-in-things-that-change-peoples-lives">Jeff Bezos's advice to invest in things that change people's lives</a>. This approach led Shaq to invest in companies like Ring and Lyft, leveraging his celebrity status to gain early access to promising ventures.&nbsp;
However, not all his business decisions were hits. He passed on investing in Starbucks, believing at the time that "Black people don't drink coffee." He later admitted this was one of his biggest business regrets.
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
Shaq's commitment to authenticity is evident in his business choices. He sold his <a href="https://www.benzinga.com/startups/24/12/42468734/nba-legend-shaq-owned-17-auntie-annes-franchises-but-sold-them-after-realizing-black-people-dont-like-pretzels-that-much">17 Auntie Anne's pretzel franchises</a>, explaining on the "<a href="https://youtu.be/XByJpQzl2DY?si=-dFFd6BsJFCji1ot">Earn Your Leisure Podcast</a>," "Black people don't like pretzels that much. So I had to switch it up."
But the missteps don't outshine the bigger picture. He buys laptops for kids he just met. Pays for strangers' funerals. Picks up the tab for young fans <a href="https://www.benzinga.com/personal-finance/25/01/43077262/nba-legend-shaq-spotted-a-young-man-buying-an-engagement-ring-in-zales-when-he-swooped-in-and-paid-for-it-tell-your-girlfriend-i-got-it">buying engagement rings</a>. And he never posts about it—he lets the people on the receiving end do the talking.
In 2021, his <a href="https://www.benzinga.com/personal-finance/25/03/44207096/shaq-said-his-krispy-kreme-store-was-likely-burned-down-by-homeless-trying-to-stay-warm-im-not-gonna-be-putting-charges-on-homeless-people">Krispy Kreme store in Atlanta was destroyed by fire</a> for a second time, Shaq didn't flinch. Authorities believed homeless individuals had started the blaze trying to stay warm. He chose not to press charges.
Shaq may not have become sheriff like he once hoped, <a href="https://www.benzinga.com/personal-finance/25/03/44380108/trust-me-im-reading-what-hes-doing-every-day-nba-legend-shaq-with-a-500-million-net-worth-swears-by-warren-buffetts-investing-wisdom">but with a $500 million net worth</a> and a reputation built on real connection, he hardly needed the badge. When he says he can talk business with Gates and friends from the "hood"—he means it. And that range? That's not a gimmick. It's why people trust him, invest with him, and invite him into conversations that actually move things forward.
Read Next:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.</li>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
</ul>
Photo: Shutterstock

NBA Legend Shaq Says He Can 'Throw On a Suit And Have A Conversation With Bill Gates' Then Head to the Hood and Talk to the 'Homies'

Moodys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) has outperformed the market over the past 20 years by 4.45% on an annualized basis producing an average annual return of 12.52%. Currently, Moodys has a market capitalization of $78.92 billion. 
Buying $100 In MCO: If an investor had bought $100 of MCO stock 20 years ago, it would be worth $1,065.00 today based on a price of $438.62 for MCO at the time of writing.
<h3>Moodys's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745620214_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Moodys 20 Years Ago Would Be Worth This Much Today

Liberty Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) has outperformed the market over the past 5 years by 13.64% on an annualized basis producing an average annual return of 27.66%. Currently, Liberty Energy has a market capitalization of $1.97 billion. 
Buying $100 In LBRT: If an investor had bought $100 of LBRT stock 5 years ago, it would be worth $368.79 today based on a price of $12.16 for LBRT at the time of writing.
<h3>Liberty Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745619310_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LBRT

Here's How Much You Would Have Made Owning Liberty Energy Stock In The Last 5 Years

Southern Copper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>) reported quarterly earnings of $1.19 per share which beat the analyst consensus estimate of $1.09 by 9.17 percent. This is a 30.77 percent increase over earnings of $0.91 per share from the same period last year. The company reported quarterly sales of $3.12 billion which beat the analyst consensus estimate of $2.96 billion by 5.51 percent. This is a 20.08 percent increase over sales of $2.60 billion the same period last year.

Earnings

Earnings Beats

SCCO

Southern Copper Q1 EPS $1.19 Beats $1.09 Estimate, Sales $3.12B Beat $2.96B Estimate

Coca-Cola Femsa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOF#NYSE">KOF</a>) reported quarterly earnings of $1.20 per share which missed the analyst consensus estimate of $1.37 by 12.41 percent. This is a 14.29 percent decrease over earnings of $1.40 per share from the same period last year. The company reported quarterly sales of $3.43 billion which missed the analyst consensus estimate of $3.45 billion by 0.52 percent. This is a 8.70 percent decrease over sales of $3.76 billion the same period last year.

Earnings Misses

Coca-Cola Femsa Q1 EPS $1.20 Misses $1.37 Estimate, Sales $3.43B Miss $3.45B Estimate

Throughout the last three months, 13 analysts have evaluated Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">3</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">2</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $36.85, a high estimate of $68.00, and a low estimate of $21.00. This upward trend is apparent, with the current average reflecting a 32.7% increase from the previous average price target of $27.77.
<img src="https://www.benzinga.com/files/images/story/2025/1745618458_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Hims &amp; Hers Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Daniel Grosslight &#x7C;Citigroup &#x7C;Lowers &#x7C;Sell &#x7C; $25.00&#x7C;$27.00 &#x7C; 
&#x7C;Jailendra Singh &#x7C;Truist Securities &#x7C;Lowers &#x7C;Hold &#x7C; $33.00&#x7C;$39.00 &#x7C; 
&#x7C;Allen Lutz &#x7C;B of A Securities &#x7C;Raises &#x7C;Underperform &#x7C; $22.00&#x7C;$21.00 &#x7C; 
&#x7C;Allen Lutz &#x7C;B of A Securities &#x7C;Maintains &#x7C;Underperform &#x7C; $21.00&#x7C;$21.00 &#x7C; 
&#x7C;Daniel Grosslight &#x7C;Citigroup &#x7C;Maintains &#x7C;Sell &#x7C; $27.00&#x7C;$27.00 &#x7C; 
&#x7C;Jailendra Singh &#x7C;Truist Securities &#x7C;Raises &#x7C;Hold &#x7C; $39.00&#x7C;$24.00 &#x7C; 
&#x7C;Michael Cherny &#x7C;Leerink Partners &#x7C;Raises &#x7C;Market Perform &#x7C; $40.00&#x7C;$24.00 &#x7C; 
&#x7C;Korinne Wolfmeyer &#x7C;Piper Sandler &#x7C;Raises &#x7C;Neutral &#x7C; $35.00&#x7C;$24.00 &#x7C; 
&#x7C;Ryan MacDonald &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $61.00&#x7C;$31.00 &#x7C; 
&#x7C;Daniel Grosslight &#x7C;Citigroup &#x7C;Raises &#x7C;Sell &#x7C; $27.00&#x7C;$25.00 &#x7C; 
&#x7C;Allen Lutz &#x7C;B of A Securities &#x7C;Raises &#x7C;Underperform &#x7C; $21.00&#x7C;$18.00 &#x7C; 
&#x7C;Maria Ripps &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Buy &#x7C; $68.00&#x7C;$38.00 &#x7C; 
&#x7C;Craig Hettenbach &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Equal-Weight &#x7C; $60.00&#x7C;$42.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hims &amp; Hers Health. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hims &amp; Hers Health compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Hims &amp; Hers Health's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Hims &amp; Hers Health's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HIMS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Hims &amp; Hers Health analyst ratings.</a>
<h2>All You Need to Know About Hims &amp; Hers Health</h2>
Hims &amp; Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.
<h3>Understanding the Numbers: Hims &amp; Hers Health's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Hims &amp; Hers Health's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 95.09%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Hims &amp; Hers Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 5.41%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Hims &amp; Hers Health's ROE stands out, surpassing industry averages. With an impressive ROE of 5.68%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Hims &amp; Hers Health's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.97% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Hims &amp; Hers Health's debt-to-equity ratio is below the industry average. With a ratio of 0.02, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Breaking Down Hims & Hers Health: 13 Analysts Share Their Views

Throughout the last three months, 17 analysts have evaluated Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Merit Medical Systems, revealing an average target of $114.12, a high estimate of $128.00, and a low estimate of $100.00. Observing a downward trend, the current average is 2.51% lower than the prior average price target of $117.06. 
<img src="https://www.benzinga.com/files/images/story/2025/1745618451_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Merit Medical Systems. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jon Young &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $108.00&#x7C;$127.00 &#x7C; 
&#x7C;Jayson Bedford &#x7C;Raymond James &#x7C;Lowers &#x7C;Outperform &#x7C; $108.00&#x7C;$116.00 &#x7C; 
&#x7C;Michael Petusky &#x7C;Barrington Research &#x7C;Lowers &#x7C;Outperform &#x7C; $103.00&#x7C;$111.00 &#x7C; 
&#x7C;Mike Matson &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $100.00&#x7C;$116.00 &#x7C; 
&#x7C;David Rescott &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $110.00&#x7C;$111.00 &#x7C; 
&#x7C;Jason Bednar &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $112.00&#x7C;$116.00 &#x7C; 
&#x7C;Michael Petusky &#x7C;Barrington Research &#x7C;Maintains &#x7C;Outperform &#x7C; $111.00&#x7C;$111.00 &#x7C; 
&#x7C;Mike Matson &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $116.00&#x7C;$116.00 &#x7C; 
&#x7C;Robbie Marcus &#x7C;JP Morgan &#x7C;Announces &#x7C;Overweight &#x7C; $120.00&#x7C;- &#x7C; 
&#x7C;Michael Petusky &#x7C;Barrington Research &#x7C;Lowers &#x7C;Outperform &#x7C; $111.00&#x7C;$115.00 &#x7C; 
&#x7C;Jon Young &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $127.00&#x7C;$128.00 &#x7C; 
&#x7C;Larry Biegelsen &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $117.00&#x7C;$120.00 &#x7C; 
&#x7C;Mike Matson &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $116.00&#x7C;$122.00 &#x7C; 
&#x7C;Jason Bednar &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $116.00&#x7C;$114.00 &#x7C; 
&#x7C;Michael Petusky &#x7C;Barrington Research &#x7C;Raises &#x7C;Outperform &#x7C; $115.00&#x7C;$114.00 &#x7C; 
&#x7C;Jon Young &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Buy &#x7C; $128.00&#x7C;$127.00 &#x7C; 
&#x7C;Mike Matson &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $122.00&#x7C;$109.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Merit Medical Systems. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Merit Medical Systems compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Merit Medical Systems's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Merit Medical Systems's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MMSI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Merit Medical Systems analyst ratings.</a>
<h2>Discovering Merit Medical Systems: A Closer Look</h2>
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
<h3>Merit Medical Systems's Financial Performance</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Merit Medical Systems displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 9.44%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Merit Medical Systems's net margin is impressive, surpassing industry averages. With a net margin of 7.87%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Merit Medical Systems's ROE stands out, surpassing industry averages. With an impressive ROE of 2.07%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.17%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.58, Merit Medical Systems adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

ETC 6 Meridian Mega Cap Equity ETF

Vendite allo scoperto

ETC 6 Meridian Mega Cap Equity ETF (ARCA:SIXA), Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO